FOXO Technologies Inc., a software company specializing in underwriting protocol and consumer engagement platforms, has experienced significant volatility in its stock price over the past year. The company operates globally, serving insurers, health researchers, and life science companies, leveraging epigenetic technology and insights to drive its offerings.
As of January 11, 2026, FOXO Technologies Inc. is listed on the OTC Bulletin Board, with its shares trading at a close price of $0.0002. This figure represents a substantial decline from the company’s 52-week high of $7.4625, recorded on January 15, 2025. Conversely, the stock reached its 52-week low of $0.00005 on January 11, 2026. This dramatic fluctuation underscores the pronounced price dispersion and volatility characteristic of the company’s equity.
The market capitalization of FOXO Technologies Inc. stands at $499,130 USD, reflecting its relatively small size and the limited liquidity of its shares. The significant intraday and inter-week fluctuations in the stock price highlight the heightened sensitivity of the company’s equity to market micro-dynamics, a common trait among securities with limited trading volumes.
In terms of recent developments, the company has not garnered any new media coverage as of the present date. The most recent public update from FOXO Technologies Inc. was delivered by CEO Seamus Lagan on December 15, 2025, during a year-end review to shareholders. This update provided insights into the company’s performance and strategic direction for the year.
Overall, the financial trajectory of FOXO Technologies Inc. illustrates the challenges faced by companies operating in niche markets with specialized technological offerings. The volatility in its stock price and the absence of recent media coverage suggest a cautious outlook for potential investors, emphasizing the need for thorough due diligence and consideration of market conditions.
